Cargando…
Dialysis as a Novel Adjuvant Treatment for Malignant Cancers
SIMPLE SUMMARY: There is a clear need for new cancer therapies as many cancers have a very short long-term survival rate. For most advanced cancers, therapy resistance limits the benefit of any single-agent chemotherapy, radiotherapy, or immunotherapy. Cancer cells show a greater dependence on gluco...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600214/ https://www.ncbi.nlm.nih.gov/pubmed/36291840 http://dx.doi.org/10.3390/cancers14205054 |
_version_ | 1784816786057723904 |
---|---|
author | Hobro, Sture Nilsson, Anders Sternby, Jan Öberg, Carl Pietras, Kristian Axelson, Håkan Carneiro, Ana Kinhult, Sara Christensson, Anders Fors, Jonas Maciejewski, Steven Knox, Jason Forsal, Innas Källquist, Linda Roos, Viktoria |
author_facet | Hobro, Sture Nilsson, Anders Sternby, Jan Öberg, Carl Pietras, Kristian Axelson, Håkan Carneiro, Ana Kinhult, Sara Christensson, Anders Fors, Jonas Maciejewski, Steven Knox, Jason Forsal, Innas Källquist, Linda Roos, Viktoria |
author_sort | Hobro, Sture |
collection | PubMed |
description | SIMPLE SUMMARY: There is a clear need for new cancer therapies as many cancers have a very short long-term survival rate. For most advanced cancers, therapy resistance limits the benefit of any single-agent chemotherapy, radiotherapy, or immunotherapy. Cancer cells show a greater dependence on glucose and glutamine as fuel than healthy cells do. In this article, we propose using 4- to 8-h dialysis treatments to change the blood composition, i.e., lowering glucose and glutamine levels, and elevating ketone levels—thereby disrupting major metabolic pathways important for cancer cell survival. The dialysis’ impact on cancer cells include not only metabolic effects, but also redox balance, immunological, and epigenetic effects. These pleiotropic effects could potentially enhance the effectiveness of traditional cancer treatments, such as radiotherapies, chemotherapies, and immunotherapies—resulting in improved outcomes and longer survival rates for cancer patients. ABSTRACT: Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently increase blood ketone body levels and reduce glutamine levels, which may further reinforce the impact of the KC. Importantly, ketones also induce epigenetic changes imposed by histone deacetylates (HDAC) activity (Class I and Class IIa) known to play an important role in cancer metabolism. Thus, dialysis could be an impactful and safe adjuvant treatment, sensitizing cancer cells to traditional cancer treatments (TCTs), potentially making these significantly more efficient. |
format | Online Article Text |
id | pubmed-9600214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96002142022-10-27 Dialysis as a Novel Adjuvant Treatment for Malignant Cancers Hobro, Sture Nilsson, Anders Sternby, Jan Öberg, Carl Pietras, Kristian Axelson, Håkan Carneiro, Ana Kinhult, Sara Christensson, Anders Fors, Jonas Maciejewski, Steven Knox, Jason Forsal, Innas Källquist, Linda Roos, Viktoria Cancers (Basel) Review SIMPLE SUMMARY: There is a clear need for new cancer therapies as many cancers have a very short long-term survival rate. For most advanced cancers, therapy resistance limits the benefit of any single-agent chemotherapy, radiotherapy, or immunotherapy. Cancer cells show a greater dependence on glucose and glutamine as fuel than healthy cells do. In this article, we propose using 4- to 8-h dialysis treatments to change the blood composition, i.e., lowering glucose and glutamine levels, and elevating ketone levels—thereby disrupting major metabolic pathways important for cancer cell survival. The dialysis’ impact on cancer cells include not only metabolic effects, but also redox balance, immunological, and epigenetic effects. These pleiotropic effects could potentially enhance the effectiveness of traditional cancer treatments, such as radiotherapies, chemotherapies, and immunotherapies—resulting in improved outcomes and longer survival rates for cancer patients. ABSTRACT: Cancer metabolism is characterized by an increased utilization of fermentable fuels, such as glucose and glutamine, which support cancer cell survival by increasing resistance to both oxidative stress and the inherent immune system in humans. Dialysis has the power to shift the patient from a state dependent on glucose and glutamine to a ketogenic condition (KC) combined with low glutamine levels—thereby forcing ATP production through the Krebs cycle. By the force of dialysis, the cancer cells will be deprived of their preferred fermentable fuels, disrupting major metabolic pathways important for the ability of the cancer cells to survive. Dialysis has the potential to reduce glucose levels below physiological levels, concurrently increase blood ketone body levels and reduce glutamine levels, which may further reinforce the impact of the KC. Importantly, ketones also induce epigenetic changes imposed by histone deacetylates (HDAC) activity (Class I and Class IIa) known to play an important role in cancer metabolism. Thus, dialysis could be an impactful and safe adjuvant treatment, sensitizing cancer cells to traditional cancer treatments (TCTs), potentially making these significantly more efficient. MDPI 2022-10-15 /pmc/articles/PMC9600214/ /pubmed/36291840 http://dx.doi.org/10.3390/cancers14205054 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Hobro, Sture Nilsson, Anders Sternby, Jan Öberg, Carl Pietras, Kristian Axelson, Håkan Carneiro, Ana Kinhult, Sara Christensson, Anders Fors, Jonas Maciejewski, Steven Knox, Jason Forsal, Innas Källquist, Linda Roos, Viktoria Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title | Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title_full | Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title_fullStr | Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title_full_unstemmed | Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title_short | Dialysis as a Novel Adjuvant Treatment for Malignant Cancers |
title_sort | dialysis as a novel adjuvant treatment for malignant cancers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600214/ https://www.ncbi.nlm.nih.gov/pubmed/36291840 http://dx.doi.org/10.3390/cancers14205054 |
work_keys_str_mv | AT hobrosture dialysisasanoveladjuvanttreatmentformalignantcancers AT nilssonanders dialysisasanoveladjuvanttreatmentformalignantcancers AT sternbyjan dialysisasanoveladjuvanttreatmentformalignantcancers AT obergcarl dialysisasanoveladjuvanttreatmentformalignantcancers AT pietraskristian dialysisasanoveladjuvanttreatmentformalignantcancers AT axelsonhakan dialysisasanoveladjuvanttreatmentformalignantcancers AT carneiroana dialysisasanoveladjuvanttreatmentformalignantcancers AT kinhultsara dialysisasanoveladjuvanttreatmentformalignantcancers AT christenssonanders dialysisasanoveladjuvanttreatmentformalignantcancers AT forsjonas dialysisasanoveladjuvanttreatmentformalignantcancers AT maciejewskisteven dialysisasanoveladjuvanttreatmentformalignantcancers AT knoxjason dialysisasanoveladjuvanttreatmentformalignantcancers AT forsalinnas dialysisasanoveladjuvanttreatmentformalignantcancers AT kallquistlinda dialysisasanoveladjuvanttreatmentformalignantcancers AT roosviktoria dialysisasanoveladjuvanttreatmentformalignantcancers |